

Kerstin Luhn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10092892/publications.pdf>

Version: 2024-02-01

8
papers

703
citations

1307594
7
h-index

1588992
8
g-index

8
all docs

8
docs citations

8
times ranked

1020
citing authors

#	ARTICLE	IF	CITATIONS
1	Safety and Immunogenicity of Novel Adenovirus Type 26 and Modified Vaccinia Ankara Vectors Vectored Ebola Vaccines. <i>JAMA - Journal of the American Medical Association</i> , 2016, 315, 1610.	7.4	266
2	Safety and Immunogenicity of a 2-Dose Heterologous Vaccination Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Uganda and Tanzania. <i>Journal of Infectious Diseases</i> , 2019, 220, 46-56.	4.0	117
3	Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial. <i>Lancet Infectious Diseases</i> , The, 2021, 21, 493-506.	9.1	115
4	Safety and Immunogenicity of a 2-Dose Heterologous Vaccine Regimen With Ad26.ZEBOV and MVA-BN-Filo Ebola Vaccines: 12-Month Data From a Phase 1 Randomized Clinical Trial in Nairobi, Kenya. <i>Journal of Infectious Diseases</i> , 2019, 220, 57-67.	4.0	75
5	Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 110-122.	9.1	48
6	Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial. <i>Lancet Infectious Diseases</i> , The, 2022, 22, 97-109.	9.1	47
7	Safety and Immunogenicity of Heterologous and Homologous 2-Dose Regimens of Adenovirus Serotype 26 and Modified Vaccinia Ankara Vectors Vectored Ebola Vaccines: A Randomized, Controlled Phase 1 Study. <i>Journal of Infectious Diseases</i> , 2022, 226, 595-607.	4.0	27
8	Assessments of different batches and dose levels of a two-dose Ad26.ZEBOV and MVA-BN-Filo vaccine regimen. <i>Npj Vaccines</i> , 2021, 6, 157.	6.0	8